Miller DS - Search Results

1

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. Among authors: miller ds. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393

2

Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.

Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Schorge JO, et al. Among authors: miller ds. Gynecol Oncol. 2001 Nov;83(2):383-7. doi: 10.1006/gyno.2001.6431. Gynecol Oncol. 2001. PMID: 11606101

3

Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.

Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO. Lea JS, et al. Among authors: miller ds. Gynecol Oncol. 2002 Jan;84(1):115-9. doi: 10.1006/gyno.2001.6473. Gynecol Oncol. 2002. PMID: 11748986

4

Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.

Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO. Lea JS, et al. Among authors: miller ds. Gynecol Oncol. 2002 Feb;84(2):285-8. doi: 10.1006/gyno.2001.6524. Gynecol Oncol. 2002. PMID: 11812088

5

Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.

Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO. Lea JS, et al. Among authors: miller ds. Gynecol Oncol. 2003 Dec;91(3):558-62. doi: 10.1016/j.ygyno.2003.08.020. Gynecol Oncol. 2003. PMID: 14675676

6

Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis.

Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY. Lea JS, et al. Among authors: miller ds. Am J Obstet Gynecol. 2004 Mar;190(3):674-9. doi: 10.1016/j.ajog.2003.09.036. Am J Obstet Gynecol. 2004. PMID: 15041998

7

Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.

Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Schorge JO, et al. Among authors: miller ds. Clin Cancer Res. 2004 May 15;10(10):3474-8. doi: 10.1158/1078-0432.CCR-03-0365. Clin Cancer Res. 2004. PMID: 15161704

8

Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.

Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO. Lavie I, et al. Among authors: miller ds. Am J Obstet Gynecol. 2005 May;192(5):1362-4. doi: 10.1016/j.ajog.2004.12.080. Am J Obstet Gynecol. 2005. PMID: 15902109

9

Fertility-sparing surgery for ovarian low malignant potential tumors.

Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Rao GG, et al. Among authors: miller ds. Gynecol Oncol. 2005 Aug;98(2):263-6. doi: 10.1016/j.ygyno.2005.04.025. Gynecol Oncol. 2005. PMID: 15964063

10

Retrospective cohort study of surgical staging for ovarian low malignant potential tumors.

Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO. Wingo SN, et al. Among authors: miller ds. Am J Obstet Gynecol. 2006 May;194(5):e20-2. doi: 10.1016/j.ajog.2005.11.033. Epub 2006 Apr 21. Am J Obstet Gynecol. 2006. PMID: 16647891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page